Candidate ranking
Compare matched antibodies, bispecifics, fragments, or shuttle-cargo constructs using harmonized dosing, sampling, and detection conditions.
Antibody Brain-Shuttle Screening Using Human BBB Models
Neurost provides human blood-brain barrier screening services to compare antibody and antibody-shuttle candidates for receptor-mediated uptake, intracellular trafficking, and apical-to-basolateral transport. The service supports early discovery, format and affinity comparison, mechanism-focused studies, and candidate prioritization through customized model selection, experimental controls, quantitative analysis, and collaborative study design.
Screen transport, not signal alone
Separate productive BBB passage from uptake and leak
A strong cell-associated antibody signal does not necessarily indicate productive brain-side delivery. High receptor engagement can be followed by luminal recycling, endosomal retention, or lysosomal routing, while compromised barrier integrity can create an apparent transport signal through paracellular leakage.
A fit-for-purpose screen therefore combines antibody quantification with barrier quality controls, compartment-resolved measurements, non-targeting comparators, and mechanistic perturbations. Neurost can align these elements with a project’s receptor biology, molecule format, available detection reagents, and desired screening depth. Broader model-development options are described in our human BBB model service solutions.
Service capabilities
A screening strategy built around the candidate and receptor
The study plan can be staged from an efficient comparative screen to a deeper investigation of transport mechanism and intracellular fate.
Mechanism discrimination
Use competition, receptor-blocking, temperature, time-course, dose-response, or other project-appropriate controls to test whether transport is receptor- and energy-dependent.
Format and property comparison
Evaluate how molecular architecture, target-binding behavior, valency, or relative affinity influences endothelial uptake and brain-side recovery.
Trafficking assessment
Add imaging or compartment-specific measurements to distinguish surface binding, internalization, recycling, retention, and transcytosis where the study question requires it.
Candidate and project readiness
Prepare the inputs that make a screening result actionable
A short technical review before model work helps align candidate handling, controls, detection, and ranking criteria. This reduces ambiguity when a molecule shows high cellular uptake but limited brain-side recovery, or when barrier integrity changes during exposure.
Molecule information
Format, molecular weight, valency, receptor target, species cross-reactivity, concentration, formulation, and available quantity.
Binding context
Relative affinity, epitope information, competition behavior, pH-dependent binding data, and receptor-engagement expectations when available.
Comparator strategy
Non-targeting IgG, parental cargo, receptor-binding control, format-matched control, and reference candidate selected for the intended decision.
Detection feasibility
Compatible antibodies, labels, ligand-binding reagents, or analytical methods able to distinguish intact candidate from background and degradation products.
Human BBB model options
Match model complexity to the screening decision
Cell source and configuration are selected during feasibility review. The final platform depends on receptor expression, assay sensitivity, throughput, transport route, and the degree of neurovascular context required.
| Model configuration | Best suited to | Typical decision value |
|---|---|---|
| Human endothelial monolayer / Transwell | Controlled apical-to-basolateral comparisons and efficient candidate triage | Ranks transport while enabling direct compartment sampling and barrier checks |
| Human multicellular co-culture | Studies needing endothelial support from astrocytes, pericytes, or both | Adds neurovascular-unit context to barrier phenotype and transport assessment |
| Perfused microfluidic BBB model | Flow-sensitive transport, vessel-like geometry, and membrane-free configurations | Tests candidate behavior under dynamic exposure and spatially resolved conditions |
| Human BBB organoid or 3D model | Imaging-led penetration studies and scalable 3D mechanistic questions | Supports depth-resolved analysis in a multicellular barrier architecture |
Model availability and suitability are confirmed during technical consultation; not every configuration is appropriate for every receptor or antibody format.
Study workflow
From assay fit to an evidence-based shortlist
A gated workflow keeps early comparisons efficient while reserving deeper mechanistic work for the most informative candidates.
-
01
Define
Review receptor, antibody formats, controls, sample constraints, detection options, and ranking criteria.
-
02
Qualify
Confirm model barrier phenotype and target-receptor suitability under the proposed assay conditions.
-
03
Screen
Dose candidates with matched controls and collect luminal, cellular, and brain-side samples as designed.
-
04
Interrogate
Apply confirmatory time-course, competition, blocking, trafficking, or orthogonal measurements.
-
05
Report
Deliver QC context, comparative analysis, interpretation, and a candidate-ranking summary.
Readouts and controls
Build confidence around the transport signal
The analytical package is selected around candidate concentration, available reagents, expected transport range, and the model configuration. Readouts may be combined to provide orthogonal evidence rather than relying on a single endpoint.
- TEER or project-appropriate barrier integrity assessment
- Paracellular tracer permeability
- Compartment-resolved antibody quantification
- Cellular uptake or trafficking imaging
- Non-targeting and matrix-matched controls
- Receptor-blocking or competition controls
Potential deliverables
- Study design and finalized assay matrix
- Barrier qualification and experimental QC summary
- Processed transport, uptake, and integrity data as applicable
- Comparative visualizations and candidate ranking
- Technical interpretation and recommended next-step discussion
Final deliverables are specified in the approved project scope.
Tiered screening strategy
Increase model depth only when it improves the decision
A staged design can preserve candidate throughput at the start, then add mechanistic and physiological context to the most informative constructs. Each tier has a defined decision gate so that complexity follows evidence.
TIER 1
Comparative triage
Screen the broader candidate set in a sampling-friendly human endothelial configuration with matched exposure, barrier QC, and non-targeting controls.
Decision gate: identify candidates with reproducible brain-side recovery above controls without unacceptable barrier disruption.
TIER 2
Mechanism confirmation
Retest selected constructs with competition, receptor blocking, time-course sampling, dose response, or trafficking analysis tailored to the proposed transport route.
Decision gate: determine whether the observed advantage is receptor-dependent and consistent with productive transcytosis.
TIER 3
Orthogonal confirmation
Challenge the shortlist in a complementary co-culture, perfused, or 3D human BBB model when flow, multicellular context, or spatial penetration is important.
Decision gate: confirm that candidate ranking remains interpretable in a model with added physiological context.
Data interpretation framework
Interpret transport together with barrier quality and antibody fate
Candidate selection should not be driven by basolateral concentration alone. Neurost can integrate transport, recovery, cellular association, integrity, and control behavior into a comparative evidence profile.
The resulting interpretation highlights both the leading candidates and the reason for their ranking, while flagging profiles that require reformulation, repeat testing, or a different mechanistic experiment.
| Observed profile | Interpretive question | Possible next step |
|---|---|---|
| High uptake, low brain-side recovery | Is the antibody retained, recycled, or routed toward degradation? | Add trafficking or time-resolved compartment analysis |
| High recovery with barrier change | Could the signal reflect paracellular leakage? | Repeat with stricter integrity criteria and matched tracer controls |
| Transport above control, blocked by competitor | Is the advantage consistent with receptor-dependent passage? | Confirm dose response or test in an orthogonal human BBB model |
| Strong rank across complementary models | Does the evidence support advancing the construct? | Define downstream validation based on the development program |
Why Neurost
A decision-oriented collaboration
Human-relevant study design
Model and assay choices are centered on the human receptor and the intended development question.
Mechanistic control strategy
Controls are planned to help distinguish receptor-mediated passage from nonspecific uptake and barrier compromise.
Flexible screening depth
Projects can begin with comparative triage and expand to orthogonal or mechanistic studies when supported by the data.
Integrated interpretation
Candidate ranking is reported with assay QC, model limitations, and the context needed for the next decision.
Request a Quote
Fill out the form below, and our expert team will contact you to design your custom project and accelerate breakthrough innovations.